The FDA and the EMA go their sep­a­rate ways on DMD: CHMP slaps down Sarep­ta but of­fers ri­val PTC an ex­pand­ed mar­ket

Eu­ro­pean and US reg­u­la­tors oc­ca­sion­al­ly take com­plete­ly con­flict­ing stands on drugs, and nowhere is that more ev­i­dent than in Duchenne mus­cu­lar dy­s­tro­phy.

To­day, Eu­rope’s CHMP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER